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Abstract  
Background & Aims: We performed genetic analyses of a multiethnic cohort of patients with 
idiosyncratic drug-induced liver injury (DILI) to identify variants associated with susceptibility.  
Methods: We performed a genome-wide association study of 2048 individuals with DILI (cases) 
and 12,429 individuals without (controls). Our analysis included subjects of European (1806 
cases and 10,397 controls), African American (133 cases and 1,314 controls), and Hispanic (109 
cases and 718 controls) ancestry. We analyzed DNA from 113 Icelandic cases and 239,304 
controls to validate our findings.  
Results: We associated idiosyncratic DILI with rs2476601, a nonsynonymous polymorphism that 
encodes a substitution of tryptophan with arginine in the protein tyrosine phosphatase, non- 
receptor type 22 gene (PTPN22) (odds ratio [OR], 1.44; 95% CI, 1.28–1.62; P=1.2x10–9 and 
replicated the finding in the validation set (OR, 1.48; 95% CI, 1.09–1.99; P=.01). The minor 
allele frequency showed the same effect size (OR > 1) among ethnic groups. The strongest 
association was with amoxicillin and clavulanate-associated DILI in persons of 
European ancestry (OR, 1.62; 95% CI, 1.32–1.98; P=4.0x10-6; allele frequency=13.3%), but the 
polymorphism was associated with DILI of other causes (OR, 1.37; 95% CI, 1.21–1.56; P= 
1.5x10–6; allele frequency=11.5%). Among amoxicillin- and clavulanate-associated cases of 
European ancestry, rs2476601 doubled the risk for DILI among those with the HLA risk alleles 
A*02:01 and DRB1*15:01.  
 
Conclusions: In a genome-wide association study, we identified rs2476601 in PTPN22 as a non-
HLA variant that associates with risk of liver injury caused by multiple drugs and validated our 
finding in a separate cohort. This variant has been associated with increased risk of autoimmune 
diseases, providing support for the concept that alterations in immune regulation contribute to 
idiosyncratic DILI. 
 
KEY WORDS:  amino acid change; GWAS; mutation; inflammation 
 
Need to Know 
 
Background: We performed genetic analyses of a multiethnic cohort of patients with 
idiosyncratic drug-induced liver injury (DILI) to identify variants associated with susceptibility 
 
Findings: We associated idiosyncratic DILI with rs2476601, a nonsynonymous polymorphism 
that encodes a substitution of tryptophan with arginine in the protein tyrosine phosphatase, non-
receptor type 22 gene (PTPN22), and validated our findings in a separate cohort. The strongest 
association was with amoxicillin- and clavulanate-associated DILI in persons of European 
ancestry; risk was doubled among cases with the with the HLA risk alleles A*02:01 and 
DRB1*15:01. 
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Implications for Patient Care: This information could be used to identify individuals at greatest 
risk for DILI. 
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Introduction 
 
Idiosyncratic drug-induced liver injury (DILI) is a rare adverse drug reaction that is an important 
cause of acute liver failure in the developed world1, 2. DILI typically occurs in 10 to 20 out of 
100,000 treated patients, and while it can lead to death, most cases resolve with discontinuation of 
the offending drug3, 4. DILI is nonetheless one of the most frequent complications in the 
development and approval of new drugs, often leading to failure in the later stages of drug 
development or regulatory actions, including post-marketing withdrawals5. 
 
A number of genome-wide association studies (GWAS) on DILI have been performed, leading to 
the discovery of significant associations with several HLA alleles that are generally drug-specific. 
For example, HLA-B*57:01 is associated with DILI in response to flucloxacillin, HLA-A*02:01 
and HLA-DRB1*15:01 are associated with amoxicillin-clavulanate (AC), HLA-B*35:02 is 
associated with minocycline, and HLA-A*33:01 is associated with terbinafine and probably 
several other drugs as well 6-9.  The association of DILI risk with HLA alleles supports a role for 
adaptive immunity in DILI.   Although no confirmed associations outside the HLA region have 
yet been identified in a GWAS10, a trend toward association with all cause DILI was recently 
observed with  a SNP (rs2476601) in the PTPN22 gene 7.  Because this variant has been associated 
with risk for a variety of autoimmune diseases, confirming this association would provide further 
support for the immune basis for DILI. 
 
The Drug Induced Liver Injury Network (DILIN) in collaboration with the International Drug 
Induced Liver Injury Consortium (iDILIC), has assembled a cohort of  2,048 DILI cases and 
12,429 population controls across three major ethnic populations (Europeans, African-Americans 
and Hispanics). After conducting a trans-ethic meta-analysis, we replicated our top associated 
SNPs on an independent European cohort of cases and performed multiple subset analyses to 
investigate their relationship with known HLA risk alleles for DILI and their effect sizes within a 
certain drug or injury type. Here, we confirm a significant association of DILI risk with rs2476601 
in the PTPN22 gene.   This is the first GWAS significant association  outside the HLA region and 
the first that appears to hold across many different classes of drugs.  Our finding supports immune 
mechanisms  having a broad role in DILI. 
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Materials and Methods 
 
We carried out a case/control association study in three different populations (Europeans, 
Hispanics and African-Americans) and then performed a meta-analysis.  
 
Cases 
 
In the current study, we analyzed 2048 DILI cases due to multiple causal drugs, including 
amoxicillin-clavulonate (AC) and flucloxacillin, collected by the iDILIC and DILIN consortia. 
Causality assessment was performed as previously reported8, 11. 1149 European cases were 
previously genotyped and analyzed by Urban et al.11 and/or Nicoletti et al.8 and 899 had undergone 
GWAS genotyping for the first time. Table S1 shows the breakdown of the case cohorts by 
recruitment center, genotyping chip and ethnicity. Clinical characteristics of the DILI subjects 
were reported in Table 1. 
DILIN Cases 
A total of 1074 DILIN cases were included, of which 443 DILIN Caucasian cases had been 
previously reported8, 11, and  631 cases, consisting of 389 European, 133 African-American and 
109 Hispanic descendants were newly genotyped12. The DILIN protocol and entrance criteria have 
been previously published12. All participants provided written informed consent. Causality 
assessment was performed as previously described, and only cases considered probably, highly 
likely, or definitely related to the implicated drug were included13.  DNA was extracted from 
lymphocytes and stored at the NIDDK biosample repository at Rutgers University, Piscataway, 
NJ. Genome-wide genotyping for the 564 DILIN cases was performed with the Multi Ethnic 
Genome Illumina Array at Duke University and for 32 African Americans and 35 Hispanic DILIN 
cases was performed with the 1Million Illumina duo Array at Duke University.  
iDILIC European Cases 
A total of 974 European iDILIC cases with a range of causal drugs and recruitment phases were 
included. Of these, 706 cases had been described previously,8, 11 while 268 cases due to 
flucloxacillin or AC were newly genotyped. The 268 patients were recruited between May 2009 
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and May 2013 as a part of an international collaborative study involving international recruitment 
centers. All participants provided written informed consent, and each study had been approved by 
the appropriate national or institutional ethical review boards. The clinical inclusion criteria for all 
cases were those described by Aithal et al.14 The iDILIC cases were evaluated by application of 
the Council for International Organizations of Medical Science (CIOMS) scale, also called the 
Roussel Uclaf Causality Assessment Method (RUCAM),15 and by expert review by a panel of 
three hepatologists. Only cases having at least possible causality (score ≥3) were included in the 
study. DNA was prepared as described previously6. Genome-wide genotyping of the additional 
iDILIC cases was performed by the Broad Institute, Boston by Infinium HumanCoreExome 
BeadChip for 167 cases and by Infinium Human OmniExpress BeadChip for 101 cases.  
 
Clinical characteristics of the DILI cases 
 
We collected additional clinical information to further investigate the relevance of the most 
significant associations. Time from start of medication to DILI recognition, concomitant 
medications, and  maximum serum levels of alkaline phosphatase (ALP) and (ALT) were available 
for both DILIN and iDILIC cases. Also available on all cases was whether the injury was 
hepatocellular, cholestatic or mixed (based on the initial R value15 .  Specific diagnosis of 
autoimmune diseases was recorded for iDILIC cases, while DILIN cases included reports on 
whether patients had a general history of autoimmune/collagen vascular disease (Yes/No).  
 
Controls 
 
As DILI has a very low incidence, we consider that a large set of general population control 
samples can overcome the potential bias of inclusion of people who may have experienced 
unrecorded DILI events. 10,397 European controls described in our previous study8 were used. 
Moreover, data for 1,314 African American and 718 Hispanic controls were obtained from the 
MESA study (phs000420.v6.p3) in dbGAP.16 Table S1 also shows the breakdown of the control 
cohorts by genotyping chip and ethnicity.  
 
Genetic analysis 
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Quality control (QC) checks on the initial genotype data were performed as summarized in  
Supplemental Materials and Methods. EIGENSTRAT analysis was used to identify the Caucasian, 
African-American and Hispanic cohorts. Our final sample sizes were 1,806 cases and 10,397 
controls of European ancestry, 133 cases and 1,314 controls of African-American ancestry, and 
109 cases and 718 controls of Hispanic ancestry. SNP imputation was performed in batches 
dividing the samples according to ethnicity and genotyping platforms. For each batch imputation 
was carried out using Michigan Imputation Server17.  as described in the Supplementary Materials 
and Methods. For HLA genotypes, four digit HLA alleles were inferred using HIBAG18. 
 
Association analyses were performed using logistic regression under the additive model in Plink 
19. EIGENSTRAT axes were used as covariates. A meta-analysis of the three ethnic groups was 
performed using GWAMA fixed effects. Variants that 1) had a concordant effect in at least two of 
the ethnic groups and that 2) showed final meta p-values below 5x10-8 were considered statistically 
significant20, 21. The top associated imputed SNPs were genotyped in the available cases using a 
TaqMan® SNP genotyping assay (ThermoFisher Scientific, Waltham, MA) in accordance with the 
manufacturer's recommendations.  
 
Multi-marker association analysis among the combinations of carriage groups of known HLA risk 
alleles and the PTPN22 variant allele was performed by logistic regression using principal 
component as covariates and considering the joint negative carriers as the reference group in the 
drug-specific cohorts (such as AC, Flucloxacillin, Terbinafine and Flupirtine). Moreover, after 
transforming the quantitative clinical variables (latency, maximum ALP and  maximum ALT) to 
improve normality, we applied a linear regression model to test  differences among known HLA 
risk alleles and PTPN22 variant in AC cohort.  
 
Epistasis analysis was performed by logistic regression, using principal component axes as 
covariates and considering an interaction term between being a carrier of any HLA risk alleles and 
being a carrier of the associated variant.  
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We also performed association analysis between the PTPN22 variant and reported clinical 
variables. First, we treated latency and other clinical variables as a quantitative trait. After 
transforming the quantitative variables to improve normality, we applied a linear regression model 
to test PTPN22 variant effect on clinical trait in a cases-only design. Epistasis, multi-markers and 
multinomial logistic regression analyses were carried out using STATA15. 
 
Icelandic DILI replication cohort 
 
An independent Icelandic DILI replication cohort was recruited at the National University Hospital 
of Iceland. The Icelandic DILI cases were evaluated in accordance with iDILIC causality 
assessment criteria8. Clinical characteristics of the Icelandic  DILI subjects are reported in Table 
S2. The cohort included 113 DILI cases and 239,304 population controls. Geneotyping data from 
the icelandic sample set was imputed as previously described 22,23, 24. HLA alleles were also 
imputed by Graphtyper25. Logistic regression under an additive model was used to test for 
association between variants and DILI. Detailed description of Icelandic analyses is reported in 
the Supplementary Materials and Methods.   
 
 
Results 
 
Overall findings 
Our final meta-analysis included 3,622,749 SNPs in 2,048 cases and 12,429 controls (see QQ plots 
in Figure S1). Clinical characteristics of the well-phenotyped DILI cases across three main 
ethnicities are reported in Table 1.  We identified a significant association with rs2476601 
(chr1:114377568>A/G), a polymorphism changing tryptophan to arginine at codon 620 of 
PTPN22 (OR 1.44 95%CI [1.28-1.62] P=1.2x10-9; Figure 1). The enrichment was observed across 
all ethnic groups analyzed in our study, although the low number of African-American and 
Hispanic cases limited the power to identify a significant association for variants with an OR < 2 
(Table 2). Similar odds ratios were also evident within subgroups of European ancestry (Table S3). 
Independent genotyping of available DILIN cases across ethnicities (N=1070) confirmed the 
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GWAS genotypes for rs2476601 with a concordance rate of 100% (Table S4). rs2476601 was also 
found to increase the risk of DILI in the independent Icelandic replication cohort (AF = 0.13 in 
113 cases vs 0.09  in 239,304 controls), having an effect size that was comparable to that of the 
discovery cohort (OR=1.48, 95%CI [1.09-1.99] P= 0.01).  
 
In addition to rs2476601, several variants in the MHC region were found to have genome-wide 
significant p-values, led by rs3129880 (OR=1.48 95%CI [1.36-1.60] P=1.2x10-20). This variant is 
a proxy of HLA-DRB1*15:01 (r2 = 0.56) consistent with the large number of AC DILI cases in 
the cohort. As expected based on inclusion of 195 flucloxacillin and 444 AC Caucasian DILI cases, 
the most significant HLA risk alleles were HLA-B*57:01, followed by HLA-DRB1*15:01 (OR = 
2.19, P = 1.4x10-18, see Table 2). Unlike the rs2476601 association, HLA association signals were 
specific for the European population in which flucloxacillin and AC cases were the most abundant.  
 
Subsequent genome-wide conditional analysis incorporating the genotypes of the four well-
established DILI HLA risk alleles (HLA-B*57:01, HLA-DRB1*15:01, HLA-A*02:01 and HLA-
A*33:01)6-8 as covariates was undertaken to identify novel independent risk factors. The analysis 
revealed that rs2476601 remained the most significant independent risk variant (OR=1.45 95%CI 
[1.30-1.64] P = 7.6x10-10, Figure 1B and Table S5).  Similarly, the independence between 
rs2476601 and the main HLA risk alleles was confirmed in the Icelandic cohort in a multivariate 
regression model (OR=1.54; P = 0.013, Table S6). When controlling for the four major known 
DILI HLA risk alleles, HLA-C*04:01 was the most significant independent HLA allele associated 
with DILI risk reaching near statistical significance when corrected for the total number of imputed 
HLA alleles (OR=1.21; 95%CI [1.09-1.37]; P = 6.3x10-4). HLA-C*04:01 association showed 
consistent trends across all three ethnicity groups (European P=0.004, OR=1.19; African-
American P=0.02, OR=1.42; Hispanic P=0.53, OR=1.13, Table S7). Data for individual drugs in 
relation to this risk association are shown in Table S8. It is notable that the greatest association 
was seen with the 58 cases where DILI was attributed to herbal and dietary supplements (OR 2.24, 
p = 0.0008, individual agents listed in Table S9). 
We also found that rs72631546, an intergenic marker on chromosome 2, was the third most 
significant variant (OR = 1.84, P = 1.2x10-7, Table 2). rs72631546 is in LD (r2 = 0.5) with 
rs72631567, which was a SNP previously suspected to be associated with DILI risk 8. The 
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rs72631546 association was consistent between Europeans and Hispanics (OR = 1.79 P = 1.9x10-
6; OR = 2.07 P = 0.003 respectively) and was independent of the known HLA risk associations 
(OR = 1.87 P = 6.0x10-8).  
 
Association with PTPN22 rs2476601 
In the European cohort, the AC cases showed the most significant association with rs2476601 
(OR=1.62 95%CI [1.32-1.98] P = 4.0x10-6) with higher frequency than European controls (AF = 
0.13 vs AF = 0.08, respectively). We also found evidence that the association was consistent 
among the remaining of European DILI cases (N=1362 OR= 1.37 95%CI [1.21-1.56] P= 1.5x10-
6, AF= 0.11, Figure S2), and it did not appear to be driven by particular drugs or categories of 
drugs (Table 3). Significance of P £ 0.05 was seen for cases due to several causal drugs including 
sulfamethoxazole-trimethoprim (P= 0.01) and terbinafine (P= 0.01). On the other hand, cases 
related to drugs such as flucloxacillin and diclofenac, which were well represented in the cohort 
as causal agents, showed smaller increases in minor allele frequency (AF) compared with controls, 
which were not statistically significant (P > 0.05). We also evaluated the relationship of rs2476601 
genotype to DILI phenotype. Of our European ancestry cases, 45% had a hepatocellular pattern of 
injury, and 55% were cholestatic or mixed. We found enrichment compared to controls for 
rs2476601 in both injury patterns, with similar AF and ORs (hepatocellular AF = 0.12, OR=1.38, 
P = 0.0001; cholestatic/mixed AF = 0.13, OR = 1.50, P = 6.5x10-8; Table S10). We also found that 
there was a trend for the frequency of rs2476601 to be higher in the DILI cases most confidently 
ascribed to the implicated drug (Figure S2).  We found that there was no significant association 
between rs2476601 and time of onset of DILI relative to starting treatment with the implicated 
drug as well as maximum ALP or  maximum ALT values. 
 
Assessment of correlation with autoimmune diseases 
As rs2476601 has been previously associated with numerous autoimmune diseases26 we 
investigated whether the presence of autoimmune diseases in our DILI cohort could have 
contributed to the associations observed. We identified 567 DILI subjects with evidence of 
autoimmune diseases; 135 of whom had a documented history of autoimmune/collagen vascular 
disease, and the remaining subjects were suspected to have an autoimmune disease because they 
had been treated with at least one drug commonly used in these conditions, usually in addition to 
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the agent implicated as causing DILI (list of potential autoimmune treatments is presented in Table 
S11). When all 567 samples with known or suspected diagnosis of autoimmune disease were 
excluded from our cohort,  the rs2476601 association remained highly significant with the same 
effect size (n=1245, OR =1.40 95%CI [1.23-1.60] P=6.4*10-7, Table S12).   
  
Assessment of correlation with known HLA risk alleles 
We found an enrichment of rs2476601 among European DILI cases due to causal drugs known to 
have HLA alleles as the main genetic risk association (e.g., flucloxacillin, terbinafine, fenofibrate, 
minocycline, sertraline, AC) compared to the rest of the cases (OR =1.52 vs OR = 1.38, Table 
S13). Among these drugs associated with HLA risk alleles, AC was the major causal drug (444 
cases) and showed the strongest association with rs2476601 (OR=1.62 95%CI [1.32-1.98] P = 
4.0x10-6). AC-drug specific conditional analysis on HLA-A*02:01 and HLA-DRB1*15:01 
confirmed that rs2476601 was an independently associated risk factor from the known HLA risk 
alleles (OR = 1.6 and P = 8.9x10-6, Table S5). Since the three markers were independent among 
each other, we looked for evidence of co-occurance of rs2476601 and the known HLA risk alleles. 
We therefore stratified AC cases and controls based on HLA allele carriage (Table S14). There 
was evidence that carriers of rs2476601 were enriched in AC DILI patients who carried one or 
both the HLA.  In agreement with this finding, multi-marker analysis on the AC cohort confirmed 
that when rs2476601 co-occurred with either of the two HLA alleles, this consistently enhanced 
the association with DILI risk by almost two-fold compared to risk associated with the HLA alleles 
alone or in combination (Table 4). Joint carriage of the three markers was associated with a 13-
fold higher DILI risk compared to the negative carriers. We had only 12 AC cases carrying only 
rs2476601 and neither of the two HLA risk alleles.  This limited number did not allow us to capture 
the association of  rs2476601 alone with AC DILI risk, but the 95% confidence interval reported 
in Table 4 included an OR of 1.5 . Moreover, when we compared the triple positive carrier against 
HLA-A*02:01 and HLA-DRB1*15:01 positive  but rs2476601 negative group we found a 
significant 1.7 fold increase in the association with DILI risk (OR= 1.8 95%CI[1.24-2.60] ; P= 
0.002). This confirmed that rs2476601 is independently associated with AC DILI risk. Finally, we 
tested the presence of a SNP-HLA interaction effect for AC DILI. The analysis showed that there 
was an epistatic effect between rs2476601 and the presence of at least one of the HLA risk alleles 
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(OR = 1.9; P = 0.05). In otherwords, the joint effect of one or both HLA risk alleles and rs2476601 
was more than additive.  
Multi-marker analysis on the terbinafine, flucloxacillin and flupirtine cohorts also supported 
rs2476601 as independently associated with DILI  risk , showing consistent ORs in DILI due to 
flucloxacillin (OR=1.3), terbinafine (OR=3.4) and flupirtine (OR=2.5) in addition to the enhanced 
the DILI risk  associated with the known HLA alleles (Table S15). We also examined whether 
subjects in the AC cohort who carried any combination of the three risk alleles differed in clinical 
phenotype (see Materials and Methods) from each other or from individuals not carrying any of 
the three alleles. No differences were apparent.  
 
 
 
Discussion 
 
Here, we report the results of the largest DILI GWAS to date based on 2048  DILI cases and 12,429 
controls. Our analyses identified a robust association with a variant in PTPN22, a tyrosine 
phosphatase that has been linked to numerous autoimmune disorders26. Additionally, the 
association was not limited to a certain drug or pattern of injury, instead showing associations 
across the entire cohort. Moreover, we showed that the PTPN22 variant added to the DILI risk 
associated with known HLA alleles, increasing the association with AC DILI risk almost two-fold 
and appearing to have a similar effect on other DILI events with known HLA risk alleles. This 
finding provides new insights into DILI etiology and highlights the potential role of non-HLA 
variants in immune related genes as risk factors for DILI across a broad spectrum of causal drugs. 
 
rs2476601 is associated with increased risk of type 1 diabetes mellitus, rheumatoid arthritis, 
systemic lupus erythematosus, vitiligo and Graves’ disease, among others, but is also associated 
with decreased risk of Crohn's disease and Behçet disease26. This is the first confirmed genome-
wide association with DILI risk that lies outside the MHC locus and is the first variant that appears 
to generally predispose to DILI as opposed to DILI due to specific drugs. The replication of the 
association in separate Icelandic cases and controls where the PTPN22 variant is relatively 
common confirmed the association.  
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Our previous study also suggested that rs2476601 might be associated with risk for DILI, but the 
variant did not meet the criteria for genome-wide significance7. The present study confirmed that 
association, and with a larger sample size the strength of the association exceeded the required 
statistical threshold for a variant of this moderate effect size. It should be noted that the effect size 
seen for this variant with DILI was similar to those seen for other disease conditions where 
rs2476601 is associated with increased risk27. The frequency of rs2476601 varies greatly from 
population to population, being as high as 15% in Finns and as low as <0.01% in East Asians28. 
Here, we found that the frequency of the variant in DILI cases was higher in each population 
studied relative to the frequency in a matched control population, with the odds ratio remaining 
similar among different ethnic and racial populations. Despite this consistency of the odds ratio, 
the relatively small effect size of this variant means that larger sample sizes are needed to confirm 
the associations as real in all populations and with different agents responsible for causing DILI. 
The largest subset of the current study was Northern Europeans (n=1,107 cases and 5,090 
controls), where a very strong signal for this variant was seen (P=3.6x10-6, OR=1.41, Table S3). 
The other analyzed ethnicities, which had much smaller sample sizes, did not produce p-values 
below 0.05 despite their similar odds ratios for the effect of this variant.  
 
Because patients with autoimmune disease may take more medications than others, there was a 
possibility that the association we observed with rs2476601 could actually be due to an increased 
prevalence of autoimmune diseases in DILI patients. To address this possibility, we identified 
cases with a recorded or suspected (based on concomitant medications) diagnosis of autoimmune 
diseases. Although rs2476601 in these patients had a slightly higher effect size, the association 
remained comparably strong even among patients not known or  suspected to have underlying 
autoimmune conditions. Because history of autoimmune diseases was not systematically collected 
in all subjects, and because patients with autoimmune diseases may not be taking medication 
treatment for these conditions at the time of the DILI event, we cannot rule out the possibility that 
some of our DILI patients had undiagnosed and untreated autoimmune conditions.    
 
The association with rs2476601 was consistent across various phenotypes in our cohort, including 
injury patterns (cholestatic or mixed vs. hepatocellular), causal drugs, and strength of causality 
Cirulli PTPN22 variant in DILI 16 
assessment. However, we did not find any association with other features, including DILI latency.  
We found that AC cases and other cases with the highest causality scores tended to have the highest 
frequencies for rs2476601. As DILI is a diagnosis of exclusion, it is unavoidable to have some 
uncertainty about the true cause of liver injury in certain patients, and so for real risk associations, 
we expect to see the strongest associations in those cases with the highest causality score. In our 
cohort, most AC cases were classified as having a high likelihood of DILI since the AC-DILI 
characteristic phenotypes have been well defined29. The higher allele frequency in AC cases likely 
reflects a higher proportion of patients who truly have DILI due to this drug. However, there may 
be an AC-specific genetic effect of rs2476601, as AC cases had a higher allele frequency than did 
other DILI cases even when restricting to the same causality probability categories.  
 
 
Our analysis showed that rs2476601 appears to be  associated with DILI risk regardless of which 
HLA alleles are associated with DILI risk. This is also the case with autoimmune diseases where 
rs2476601 is associated across diseases that are themselves associated with different HLA 
alleles26.  This effect is consistent with the fact that PTPN22 controls events downstream from 
HLA presentation of neoantigen as summarized in Burn et al 30. PTPN22 encodes lymphoid protein 
tyrosine phosphatase (Lyp) which is expressed exclusively in immune cells. Although the 
mechanisms whereby the rs2476601 variant reduces immune tolerance are not clear, Lyp is 
involved in T-cell receptor signaling, acting at several intermediate points in the signaling cascade.  
Lyp also appears to influence regulatory T-cell function. Considerable data now support the 
concept that DILI can result from a T-cell-mediated immune attack on the liver, presumably 
directed at HLA-presented neoantigens. This response may be initiated relatively frequently during 
treatment with drugs capable of causing DILI.  However, clinically important liver injury does not 
occur in most of these patients because immune tolerance is activated, 31, 32.  We therefore suggest 
that rs2476601 predisposes to DILI by reducing immune tolerance.  Our finding supports this 
hypothesis, since we found a significant genetic interaction effect among HLA risk alleles and 
rs2476601, detecting that the AC DILI risk associated with the joint carriage of HLA risk alleles 
and the variant is more that the sum of the risks associated with each single risk factors.  Most of 
the currently reported associations for other diseases and the PTPN22 variant also show HLA 
associations, particularly HLA class II associations which is consistent with the strong association 
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seen with AC-DILI but only a slightly increased frequency of the variant with flucloxacillin-DILI 
where the associated allele is class I. Moreover, the increased frequency of the rs2476601 variant 
in DILI cases where there was no apparent HLA association suggests the possibility of other HLA 
risk alleles yet to be discovered and/or a potential role for PTPN22 in non-T cell-mediated forms 
of DILI where other immune cells might be involved.  
 
Although the association with rs2476601 was robust, its effect size was modest. The odds ratio 
averaged about 1.3 in the various ethnic groups identified here.  However, in the 10% of the 
subjects who also carried the two known HLA risk alleles (HLA-A*02:01 and HLA-
DRB1*15:01), the risk of DILI due to AC was increased over 13-fold. Given the rarity of serious 
liver injury due to AC, despite its widespread use, genotyping for risk management is probably not 
realistic. There may be instances when genotyping for this variant together with the identified HLA 
risk alleles could improve confidence in the causality assessment  but this testing is not currently 
commercially available to our knowledge. It should also be noted that with drugs causing more 
frequent and severe liver injury, genotyping to identify 10% of a patient population at 13-fold 
increased risk of DILI might be reasonable.   
  
In addition to the rs2476601 association, we also found evidence for a novel independent HLA 
risk factor in HLA-C*04:01. This association is interesting as the allele may be a risk factor across 
ethnicities and ADR clinical phenotypes. In fact, HLA-C*04:01 has previously been shown to be 
associated with nevirapine hypersensitivity in a Malawian population,33 and in our cohort, the 
association was concordant across all three populations (Table S8) and across multiple drugs and 
herbal preparations (Table S7).  
 
In conclusion, we have identified the variant rs2476601 in the PTPN22 gene as the first robust 
genetic risk association for DILI lying outside the MHC region. In addition, this association is the 
first to be associated across a broad range of implicated drugs and across different ethnic 
backgrounds. rs2476601 is therefore the first identified general risk association for DILI. The prior 
well-established association of this polymorphism with the risk of autoimmune diseases broadens 
the role of the immune system in DILI pathogenesis and may help inform future treatment and 
prevention efforts. 
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Figure Legend: 
 
Figure 1. Manhattan plot displaying the association results of (A) the meta-analysis among 
the three major populations (Europeans, African Americans and Hispanics) (B) the meta-
analysis after conditioning on the four main known HLA DILI risk alleles among the three 
major populations (Caucasians, African Americans and Hispanics). The results are reported 
for variants which had a consistent effect in Europeans and at least one of the two additional 
populations. SNPs shown in green have a significance level less than 5x10-6 and red have a 
significance level less than 5x10-8. 
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Table  
 
 
Table 1: Clinical characteristics of the samples in the three major DILI case population 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHARACTERISTICS Europeans N=1806 
Hispanics 
N=109 
African Americans 
N=133 
    
Clinical information       
Mean age, years  55  41  47  
Female, % 56.5 56.8 76.6 
Median alanine aminotransferase (range), U/L 
 
774 (9- 15065) 
 
843 (20-9108 ) 
 
780 (47- 7001) 
Median alkaline phosphatase (range) , U/L 
 
290 (11- 6239) 
 
266 (79 -2414) 265 (74- 2399) 
Median latency (range), days 
 
28 (1-7046) 
 
58 (3- 2789 ) 
 
51 (3-935) 
 
   
Injury Type       
Cholestatic (%) 463 (26%) 12 (11%) 25 (19%) 
Hepatocellular (%) 747 (41%) 73 (67%) 80 (60%) 
Mixed (%) 465 (26%) 19(17%) 22 (16%) 
Not available (%) 130 (7%) 5(5%) 6 (5%) 
 
   
 Total 1806 109 133 
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Table 2. Summary statistics for the univariate trans-ethnic meta-analysis of genome-wide 
associated variants  
Marker ALL CAU AA HISP 
OR 95%CI P OR 95%CI P OR 95%CI P OR 95%CI P 
rs2476601 1.44 1.28-
1.62 
1.2x10-9 1.42 1.27-
1.60 
9.6x10-10 1.94 0.73-
5.18 
0.19 1.91 0.94-
3.89 
0.07 
rs72631546  1.84 1.47-
2.31 
1.2x10-7 1.79 1.41-
2.27 
1.92 x10-6 - - - 2.07 1.27-
3.36 
0.003 
rs3129880  1.48 1.6-9.32 1.2x10-20 1.56 1.44-
1.69 
5.09 x10-26 0.92 0.67-
1.27 
0.62 0.97 0.68-
1.4 
0.89 
HLA-B*57:01 2.19 1.84-
2.61 
1.40 x10-18 2.24 1.94-
2.6 
4.53 x10-27 1.64 0.36-7.4 0.52 0.72 0.17-
3.02 
0.65 
HLA-DQB1*03:03 1.67 1.41-
1.99 
7.48 x10-9 1.69 1.46-
1.96 
1.27 x10-12 - - - 0.97 0.29-
3.16 
0.95 
HLA-DRB1*15:01 1.37 1.22-
1.53 
1.03 x10-7 1.40 1.27-
1.54 
3.19 x10-11 0.85 0.43-
1.69 
0.65 1.16 0.68-
1.99 
0.58 
HLA-C*06:02 1.40 1.23-
1.59 
1.88 x10-7 1.45 1.3-
1.62 
6.47 x10-11 0.92 0.58-
1.48 
0.74 1.38 0.77-
2.48 
0.28 
HLA-DQB1*06:02 1.31 1.17-
1.46 
1.47 x10-6 1.40 1.27-
1.55 
3.15 x10-11 0.90 0.66-
1.21 
0.48 1.11 0.64-
1.91 
0.72 
 
Odds ratios (OR), confidence intervals (95%CI) and p-values (P) are presented after correcting 
for population stratification with EIGENSTRAT axes within each major population. 
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Table 3. Association with rs2476601 for drugs with at least 3 case carriers in the European 
cohort and OR > 1. Drug results are ordered by p-value 
 
DRUGS # Cases AF OR 95%CI P 
Amoxacillin/Clavulanic Acid 444 0.13 1.62 1.32-1.98 0.000004 
Terbinafine 15 0.20 3.23 1.29-8.1 0.01 
Sulfamethoxazole/Trimethoprim 42 0.17 2.07 1.16-3.71 0.01 
Methotrexate 9 0.22 3.34 1.09-10.16 0.03 
Rofecoxib 6 0.25 4.08 1.05-15.82 0.04 
Valproic Acid 16 0.18 2.43 0.99-5.95 0.05 
Flupirtin 6 0.25 4.43 0.98-20.05 0.05 
Fenofibrate 10 0.20 2.93 0.97-8.87 0.06 
Erythromycin 11 0.18 2.89 0.95-8.78 0.06 
Doxycycline 6 0.25 3.21 0.85-12.1 0.09 
Pravastatin 6 0.25 3.21 0.83-12.47 0.09 
Nimesulide 20 0.12 2.10 0.81-5.41 0.12 
Cefuroxime 4 0.25 3.45 0.69-17.28 0.13 
Ethinylestradiol/Levonorgestrel 7 0.21 2.53 0.71-9.05 0.15 
Isoniazid 43 0.13 1.59 0.84-3.02 0.16 
Celecoxib 9 0.17 2.37 0.69-8.19 0.17 
Flucloxacillin 195 0.11 1.24 0.90-1.71 0.18 
Nitrofurantoin 74 0.12 1.40 0.85-2.32 0.19 
Piroxicam 5 0.20 2.85 0.60-13.68 0.19 
Gabapentin 5 0.20 2.79 0.58-13.39 0.2 
Cefazolin 21 0.14 1.59 0.67-3.8 0.3 
Mercaptopurine 10 0.15 1.72 0.50-5.97 0.39 
Imatinib 8 0.12 1.70 0.38-7.56 0.49 
Ticlopidine 5 0.10 2.01 0.24-16.73 0.52 
Atorvastatin 29 0.10 1.32 0.56-3.09 0.53 
Minocycline 32 0.11 1.29 0.58-2.86 0.53 
Interferon Beta-1a 4 0.12 1.90 0.21-16.79 0.57 
Amiodarone 5 0.20 1.64 0.28-9.73 0.59 
Diclofenac 66 0.10 1.17 0.67-2.04 0.59 
Ibuprofen 15 0.10 1.36 0.41-4.52 0.62 
Herbal and dietary products 58 0.10 1.19 0.65-2.17 0.58 
Disulfiram 8 0.12 1.40 0.32-6.13 0.65 
All Other Therapeutic Products 9 0.11 1.33 0.30-5.93 0.71 
Nicotinic Acid 4 0.12 1.45 0.17-12.17 0.73 
Lisinopril 5 0.10 1.45 0.17-12.17 0.74 
Phenytoin 10 0.10 1.18 0.27-5.11 0.82 
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Rosuvastatin 4 0.12 1.27 0.14-11.29 0.83 
Sertraline 6 0.08 1.17 0.15-9.27 0.88 
Levofloxacin 17 0.09 1.05 0.32-3.44 0.94 
 
# Cases= number of cases for each drug; AF = Allele frequcncy; OR = Odd Ratio; ULC= 95% 
lower Confidence interval of the Odds Ratio; ULC= 95% upper Confidence Interval of the Odds 
Ratio; P = logistic p-value. In bold drugs previously known to be associated with at least one HLA 
risk allele.  
 
 
Table 4 Summary statistics of the multi marker analysis performed on the carriage of 
HLA-DRB1*15:01, HLA-A*02:01 and rs2476601 in the European Amoxicillin-
Clavulanate-related DILI cohort.  
 
 Cases Controls 
 
   
Carriage 
group N CF N CF OR 95%CI P 
+/+/+ 49 0.11 187 0.02 13.80 9.18-20.71 1.1*10-36 
-/+/+ 35 0.08 625 0.06 3.03 1.99-4.63 2.3*10-7 
+/-/+ 12 0.03 206 0.02 3.28 1.74-6.19 2.5*10-4 
-/-/+ 12 0.03 663 0.07 0.95 0.51-1.77 0.8 
+/+/- 126 0.28 895 0.09 7.68 5.63-10.48 8.8*10-38 
-/+/- 101 0.23 3212 0.31 1.68 1.23-2.30 1.1*10-3 
+/-/- 41 0.09 1037 0.10 2.09 1.41-3.11 2.7*10-4 
-/-/- 68 0.15 3531 0.34 - - - 
 
Odds ratios (OR), 95% confidence intervals (95%CI) and p-values (P) are presented after 
correcting for population stratification and considering the triple negative carriers as the reference 
group. The three letters in the first column (carriage group) reflects in order the HLA-DRB1*15:01 
status, the HLA-A*02:01 status and the rs2476601 status. The risk alleles status is represented by 
“+ “ = present or “–“ = absent N = number of samples in the group; CF = carriage frequency.  
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Genome-wide association study Quality Control (QC) for each cohort 
 
QC was conducted at both single marker and subject levels before performing the SNP imputation. 
Any marker that did not pass the following criteria was excluded from analysis: (i) genotype call 
rate in the batch of subjects greater than 95%, (ii) missing genotype rate greater than 5%, (ii) p-
value for Hardy-Weinberg equilibrium greater than 10-7 in controls (if applicable). Any subject 
that did not pass the following criteria was excluded from analysis: (i) missing genotype rate < 
0.05 among the SNPs that passed QC; (ii) not a sample duplicate or closely related based on 
estimated identity-by-descent (IBD) using PLINK v 1.07  
 
Imputation 
 
We used the Michigan Imputation Server1 to impute missing genotypes separately for each 
ethnicity and for each subset genotyped by the same genotyping platform. We used the options of 
SHAPEIT for phasing, the Haplotype Reference Consortium as the reference for European 
ancestry samples and the 1000 Genomes Project as the reference for other ancestries1-5. Imputation 
methods are described in detail in the Supplementary Appendix. For HLA genotypes, four digit 
HLA alleles were inferred using HIBAG6. Sex chromosomes and mitochondria were not imputed. 
After imputation, the resulting calls were required to have R2 > 0.6, maximum genotype posterior 
and genotype missingness < 0.05 in each group and the overall cohort. Genotypes were discretized 
based on the probability (PP) > 0.9. Variants were also removed if they were found to be heavily 
influenced by genotyping chip, as determined by a logistic regression p-value < 0.005 for a 
difference between two chip types within the case or within the control cohort.  
 
Icelandic genetic analysis 
 
The current association analysis was done on 113 DILI cases and 239,304 population controls 
using software developed at deCODE genetics7 Genotypes of the Icelandic sample set were typed 
and then imputed as previously described 7,8, 9.The whole genomes of 15,220 Icelanders were 
sequenced, unveiling 40,780,213 single nucleotide polymorphisms (SNP) and short indels.  These 
variants were imputed into 151,677 Icelanders whose DNA had been genotyped with various 
 3 
Illumina SNP chips and phased using long-range phasing. Genealogical deduction of carrier status 
of 282,894 un-typed relatives of chip-typed individuals further increased the sample size for 
association analysis.. Logistic regression under an additive model was used to test for association 
between variants and disease, treating DILI as the response and expected genotype counts from 
imputation as covariates. Then those samples were used as reference for imputation of 155,250 
Icelanders genotyped with chips. Using genealogic information, the sequence variants were also 
imputed into 282,894 relatives of the genotyped individuals 10. HLA alleles were called for 28,075 
Icelanders using whole genome sequence data and Graphtyper 11. Association testing with multiple 
explanatory variables was performed using the glm function in R.  
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Table S1. Genotyping arrays used in each cohort. 
 
 
 
 
  
Phenotype Cohort Ethnicity n Genotyping	kit
Case DILIN European 296 Illumina	1MDuo
Case DILIN European 147 Infinium	HumanCoreExome
Case DILIN European 389 Illumina	MEGA
Case DILIN African	American 32 Illumina	1MDuo
Case DILIN African	American 101 Illumina	MEGA
Case DILIN Hispanic 35 Illumina	1MDuo
Case DILIN Hispanic 74 Illumina	MEGA
Case iDILIC European 361 Illumina	1MDuo
Case iDILIC European 508 Infinium	HumanCoreExome
Case iDILIC European 105 Infinium	OmniExpress
Control Multiple	sources European 10397 Multiple
Control MESA	SHARe African	American 1314 Affymetrix	Genome-Wide	Human	SNP	Array	6.0
Control MESA	SHARe Hispanic 718 Affymetrix	Genome-Wide	Human	SNP	Array	6.0
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Table S2 Demographics, type of drugs leading to liver injury and the type of liver injury in the 113 
genotyped Icelandic DILI patients. 
 
 
Carattheristics N of Cases (Frequency) 
Demographics  
Age, median (Q1, Q3) 57 (41-71) 
Females/males 51/62 
Drugs  
Antimicrobial drugs 45/113 (40%) 
Amoxicilin-clavulanate of Antimicrobials 30/45  (67%) 
Type of injury  
Cholestatic/mixed type 72/113 (64%) 
Hepatocellular type 41/113 (36%) 
In the table median is reported with Q1= as 25th percentile and  Q3 as the 75th percentile  
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Table S3. Allele frequencies of rs2476601 in different ancestry subsets of the analyzed 
samples and the gnomad database. 
 
 
OR = Odds Ratio; 95% CI = 95% confidence intervals of the Odd Ratio; P = logistic p-value. AF 
= allele frequency. Note that the stated sample sizes do not add up to the total number included in 
this study because people who did not have their genotype successfully imputed for this variant 
were excluded. *The gnomad database12 contains 123,136 exome sequences and 15,496 whole-
genome sequences from unrelated individuals sequenced as part of various disease-specific and 
population genetic studies. **“Other” includes many different types of European ancestry as 
opposed to one particular cluster. 
 
  
Ancestry group (case n / ctrl n) OR 95% CI          P 
AF 
Case 
AF 
Controls 
AF  
gnomad* 
European ancestry 1.42 1.27-1.60 9.6x10-10 0.12 0.08 0.10 
   Northern Eur. (1,107 / 5,090) 1.41 1.22-1.63    3.6x10-6 0.13 0.09 - 
   Southern Eur. (209 / 2,518) 1.1 0.75-1.61 0.63 0.07 0.07 - 
   Swedish (146 / 1,076) 1.23 0.83-1.79 0.32 0.11 0.09 - 
   Jewish (87 / 1,076) 1.57 0.78-3.16 0.21 0.07 0.04 0.05 
   Other** (256 / 292) 2.36 1.45-3.85 0.001 0.11 0.05 - 
Iceland (113/239,304) 1.48 1.09-1.99 0.01 0.13 0.08 - 
African American (133/1,314) 1.94 0.73-5.18 0.19 0.02 0.01 0.01 
Hispanic (109/718) 1.91 0.94-3.89 0.07 0.04 0.02 0.03 
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Table S4: Concordance rate between imputed and sequenced genotypes of rs2476601 by 
ethnicities (imputed vs typed) 
 
  
 
A) Europeans 
 
 
 
 
B) African Americans 
 
  
 
 
C) Hispanics 
 
 
The genotypes are coded as 0=Homozygote minor 1=heterozygote and 2-homozigote major 
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Table S5: Summary statistics for known DILI risk factors in the multiple regression model 
within each ethnicity 
   
Europeans  Variant OR 95%CI  P 
ALL cases rs2476601 1.44 1.28-1.61 7.38E-10 
  HLA-DRB1*15:01 1.47 1.33-1.63 3.98E-14 
  HLA-A*02:01 1.28 1.18-1.38 9.41E-10 
  HLA-B*57:01 2.42 2.08-2.80 4.53E-31 
  HLA-A*33:01 2.21 1.60-3.04 1.38E-06 
AC cases rs2476601 1.61 1.31-1.99 8.91E-06 
  HLA-DRB1*15:01 3.16 2.70-3.69 6.09E-47 
  HLA-A*02:01 2.15 1.86-2.48 5.21E-26 
African Americans rs2476601 2.16 0.80-5.80 0.13 
All Cases HLA-DRB1*15:01 0.93 0.46-1.87 0.84 
  HLA-A*02:01 0.58 0.36-0.91 0.02 
  HLA-A*33:01 1.23 0.56-2.67 0.61 
Hispanics rs2476601 1.88 0.92-3.85 0.08 
All cases HLA-DRB1*15:01 1.20 0.70-2.05 0.52 
  HLA-A*02:01 0.76 0.53-1.09 0.14 
  HLA-A*33:01 0.93 0.41-2.12 0.87 
  
AC cases = amoxicillin clavulanic acid cases; OR = Odds Ratio; 95% CI = 95% confidence 
intervals of the Odd Ratio; P = logistic p-value. AF = allele frequency. Odd ratio, confidence 
intervals and p-values are presented after correcting for population stratification with 
EIGENSTRAT axes and for other known HLA risk factors present in the populations. 
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Table S6: Summary statistics of rs2476601 and known HLA risk alleles in the Icelandic 
cohort 
Analysis Marker   OR 95%CI P AF 
(a)Single marker1 rs2476601 1.52 (1.08-2.14) 0.016   
 HLA-DRB1*15:01       1.43 (1.06-1.92) 0.018 0.22 
 HLA-A*33:01        1.33 (1.01-1.76) 0.045 0.30 
 HLA-A*02:01     - - - 0.001 
  HLA-B*57:01      - - - 0.04 
(b) Conditioned to known HLA risk 
alleles rs2476601 1.54 (1.10-2.17) 0.013  
 HLA-DRB1*15:01       1.43 (1.06-1.92) 0.018 0.22 
 HLA-A*33:01        1.32 (1.00-1.75) 0.051 0.30 
 HLA-A*02:01
2 -  - 0.001 
  HLA-B*57:01      1.22 (0.65-2.30) 0.541 0.04 
 
OR = Odds Ratio; 95% CI = 95% confidence intervals of the Odd Ratio; P = logistic p-value. AF 
= allele frequency. Odd ratio, confidence intervals and p-values are presented after correcting for 
population stratification with EIGENSTRAT axes and with (a) and without (b) for other known 
HLA risk factors present in the population. 
 
1 Results are shown for markers with significant effect 
 
2The frequency of HLA-A*02:01 is extremely low rendering the result in the joint model 
meaningless. 
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Table S7. The most associated HLA risk alleles after conditioning on the four known HLA 
DILI risk alleles. 
 
HLA allele OR LCI UCI P Effects 
HLA-C*04:01 1.22 1.09 1.37 6.63E-04 +++ 
HLA-DRB1*04:01 0.78 0.67 0.90 9.30E-04 --- 
 
OR = Odds Ratio; ULC= 95% lower Confidence interval of the Odd Ratio; ULC= 95% upper 
Confidence Interval of the Odd Ratio; P = logistic p-value; Effects = effect in the three populations 
(Caucasians, African Americans and Hispanics) where + means a positive effect with OR > 1 and 
–means a negative effect with OR < 1. 
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Table S8. Statistics for HLA-C*04:01 in Europeans for drugs with at least OR > 1.2.  
 
DRUGS N OR LCI UCI P 
Herbal and dietary preparations 58 2.24 1.40 3.59 0.0008 
Methyldopa 5 8.09 2.28 28.67 0.001 
Methotrexate 9 2.87 1.03 8 0.044 
Nitrofurantoin 74 1.55 0.96 2.51 0.071 
Lisinopril 5 3.78 0.89 16.02 0.071 
Piroxicam 5 3.2 0.83 12.27 0.091 
Atorvastatin 29 1.73 0.88 3.43 0.114 
Amiodarone 5 3.06 0.56 16.82 0.198 
Hydralazine 3 4.98 0.42 58.69 0.202 
Sevoflurane 5 2.65 0.54 12.97 0.228 
Gabapentin 5 2.41 0.5 11.62 0.274 
Minocycline 32 1.47 0.71 3.02 0.297 
Rosuvastatin 6 2.11 0.47 9.43 0.327 
Omeprazole 5 2.02 0.41 9.81 0.385 
Simvastatin 18 1.52 0.59 3.92 0.387 
Pravastatin 6 1.99 0.42 9.51 0.387 
Cefazolin 21 1.37 0.54 3.51 0.508 
Sulfamethoxazole/Trimethoprim 42 1.25 0.64 2.44 0.509 
isoniazid 43 1.21 0.62 2.34 0.575 
Phenytoin 10 1.41 0.41 4.82 0.584 
Azathioprine 37 1.22 0.59 2.54 0.598 
Duloxetine 7 1.48 0.33 6.67 0.61 
Moxifloxacin 8 1.24 0.28 5.44 0.772 
Allopurinol 4 1.35 0.17 10.97 0.778 
Interferon Beta-1a 4 1.31 0.14 11.77 0.812 
 
OR = Odd Ratio, OR are from logistic regression including EIGENSTRAT axes as covariates.; 
ULC= 95% lower Confidence interval of the Odds Ratio; ULC= 95% upper Confidence Interval 
of the Odds Ratio; P = logistic p-value 
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Table S9: List of agents in herbal and dietary supplements subgroup 
 
Agents N of cases 
Unspecified Herbal 24 
Other Combinations Of Nutrients 8 
Herbal Nos W/Minerals Nos/Vitamins Nos 6 
Camellia Sinensis 2 
Garcinia Gummi-Gutta 2 
Hydroxycut/Ephedra Free 2 
Aloe Vera 1 
Amino Acids Nos 1 
Amino Acids Nos W/Capsicum Annuum Fruit/Chlor 1 
Amino Acids Nos W/Herbal Nos/Minerals Nos/Vit 1 
Carbohydrates Nos W/Creatine/Minerals Nos/Vit 1 
Cimicifuga Racemosa 1 
Ganoderma Lucidum 1 
Ginkgo Biloba 1 
Helianthus Tuberosus 1 
Herbal Nos W/Minerals Nos 1 
Herbal Nos W/Vitamins Nos 1 
Herbals Nos W/Minerals Nos/Vitamins Nos 1 
Trifolium Pratense 1 
Uncaria Tomentosa 1 
Grand Total 58 
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Table S10: Statistics for rs2476601 in Europeans stratifying the cases based on DILI 
phenotype.  
 
 
OR = Odd Ratio; ULC= 95% lower Confidence interval of the Odds Ratio; ULC= 95% upper 
Confidence Interval of the Odds Ratio; P = logistic p-value 
 
 
 
  
Cohort Number	of	cases OR LCI UCI P
HEPATOCELLULAR	cohort 747 1.39 1.17 1.64 0.0001
CHOLESTATIC/MIXED	cohort 927 1.50 1.30 1.74 6.50E-08
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Table S11 List of drugs utilized in the treatment of the autoimmune diseases that served as 
a surrogate for suspicion of autoimmune disease in the DILI subjects. 
 
Azathioprine / mercaptopurine, Cyclophosphamide, Cyclosporine, Hydroxychloroquine sulfate, 
Leflunomide, Methotrexate, Mycophenolate mofetil, Sulfasalazine/mesalazine, Apremilast, 
Tofacitinib, Tacrolimus, romiplostim and eltrombopag, levothyroxine, Propylthiouracil, 
methimazole, carbimazole, Neostigmine, etanercept, adalimumab, infliximab, certolizumab 
pegol, golimumab, Anakinra , abatacept , rituximab, and tocilizumab, canakinumab, Belimumab, 
prednisone, methylprednisolone, prednisolone 
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Table S12: Statistics for rs2476601 in Europeans stratifying the DILI cases based on whether cases had a predicted or 
reported diagnosis of autoimmune diseases previously associated with PTPN22 variant.  
 
 
#cases= number of cases, OR = Odds Ratio; ULC= 95% lower Confidence interval of the Odds Ratio; ULC= 95% upper Confidence 
Interval of the Odds Ratio; PV = logistic p-value, AF cases =Allele Frequency in cases.  
Note: the association analyses reported in the table has been performed using the same set of controls. 
  
DRUG #cases OR LCI UCI P AF cases 
Predicted autoimmune diseases based on drug history (reported 
in Table S8) 426 1.45 1.16 1.79 0.0008 0.12 
Diagnosed with autoimmune disease  135 1.64 1.15 2.33 0.006 0.14 
Both predicted and diagnosed autoimmune disease    561 1.49 1.24 1.80 2.95E-05 0.12 
no evidence of autoimmune disease 1245 1.40 1.23 1.60 6.40E-07 0.12 
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Table S13: Statistics for rs2476601 in Europeans stratifying the cases based on whether causal drugs were previously 
associated/not-associated with a HLA risk allele.  
 
 
 
OR = Odds Ratio; ULC= 95% lower Confidence interval of the Odds Ratio; ULC= 95% upper Confidence Interval of the Odds Ratio; 
PV = logistic p-value, AFcases =Allele Frequency in cases 
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Table S14: Association ofrs2476601 in European Amoxicillin-Clavulanic Acid cases stratifying based on the carriage of the two 
known HLA risk alleles.  
 
Groups #cases # Controls OR LCI UCI P AF cases 
ALL cases 444 10397 1.62 1.32 1.98 0.000004 0.14 
++ 178 1088 1.75 1.25 2.46 0.001 0.15 
-- 82 4208 1.11 0.64 1.94 0.7 0.09 
+- 56 1250 1.5 0.82 2.73 0.2 0.12 
-+ 140 3851 1.69 1.17 2.44 0.005 0.13 
 
Carriage of the HLA-DRB1*15:01 and HLA A*02:01 are expressed as “-” if absent and “+” if present following this order of HLA-
RB1*15:01 as first digit and HLA A*02:01 as second digit.  #cases = number of cases analyzed; #controls= number of controls analyzed; 
OR = Odds Ratio; ULC= 95% lower Confidence interval of the Odds Ratio; ULC= 95% upper Confidence Interval of the Odd Ratio; 
PV = logistic p-value; AF cases =Allele Frequency in cases 
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Table S15 Summary statistics of the multi marker analysis performed on the carriage of 
known HLA risk alleles and rs2476601 in the European DILI cohorts. 1) Terbinafine DILI 
cohort where the known risk allele is HLA-A*33:01, 2). Flucloxacillin DILI cohort where the 
known risk allele is HLA-B*57:01 and 3). Flupirtine DILI cohort where the known risk is 
the HLA-DRB1*16:01-DQB1*05:02 haplotype.  The -/+ symbols in the first column  reflect in 
order the known HLA risk allele status and the rs2476601 status.  
 
1)Terbinafine 
 Cases Controls    
  N CF N CF OR* LCI UCI 
++ 3 0.20 30 0.003 208.4 42.95 1011.30 
-+ 3 0.20 1,651 0.16 3.4 0.79 14.30 
+- 4 0.27 184 0.02 50.1 11.97 210.13 
-- 5 0.33 8,491 0.82 - - - 
        
2)Flucloxacillin Cases Controls    
  N CF N CF OR LCI UCI 
++ 34 0.17 109 0.01 77.96 44.70 135.97 
-+ 8 0.04 1,572 0.15 1.31 0.59 2.90 
+- 125 0.64 665 0.07 55.91 36.36 85.99 
-- 27 0.13 8,050 0.77 - - - 
        
3) Flupirtine Cases Controls    
  N CF N CF OR* LCI UCI 
++ 2 0.33 27 0.003 309.52 5.32 315.22 
-+ 1 0.17 1641 0.16 2.55 0.23 28.10 
+- 1 0.17 260 0.03 16.07 1.45 177.80 
-- 2 0.33 8,357 0.80 - - - 
 
Odds ratios (OR), 95% confidence intervals (95%CI) and p-values (P) are presented after correcting for 
population stratification and considering the double negative carriers (--)as the baseline group. N = number 
of samples in the group; CF = carriage frequency, *OR and CI are indicative of a trend since the number of 
cases from those drugs is very limited. 
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Figure S1: QQ plots for (a) the overall original analysis (b) conditional analysis.  
 
(a)                                                                      (b) 
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Figure S2. rs2476601 allele frequency across different subsets of our cohorts. Allele 
frequencies by causal drug and likelihood of DILI as described in methods. Error bars represent 
95% confidence intervals.  
 
 
The current stratification analysis based on causality score has been done dividing the cases by 
grouping DILIN “definite and highly likely” cases and iDILIC “highly probable” cases and 
grouping DILIN/iDILIC “probable” cases and grouping DILIN/iDILIC “possible” cases. PV= p-
value 
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Victoria, Universidad de Málaga, Málaga, Spain and CIBERehd, Madrid, Spain; Fernando 
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Ninewells Hospital and Medical School, Dundee, UK; Christopher P. Day, Institute of Cellular 
Medicine, Newcastle University, Newcastle upon Tyne, UK; Par Hallberg, Uppsala University, 
Uppsala, Sweden; Nelia Hernández, Universidad de la Republica, Montevideo, Uruguay; Luisa 
Ibanez, Hospital Universitari Vall d'Hebron, Barcelona, Spain ; Gerd A. Kullak-Ublick, 
University of Zurich, Zurich, Switzerland; Tarja Laitinen, Helsinki University Central Hospital, 
Helsinki, Finland; Dominique Larrey, Hôpital Saint Eloi, Montpellier, France; M. Isabel Lucena, 
IBIMA Hospital Universitario Virgen de la Victoria, Universidad de Málaga, Málaga, Spain and 
CIBERehd, Madrid, Spain; Anke Maitland-van der Zee, AMC, Amsterdam, Netherlands; 
Jennifer H. Martin, University of Newcastle, Newcastle, NSW, Australia; Dick Menzies, MUHC 
and McGill University, Montreal Chest Institute, Montreal, Canada; Mariam Molokhia, King's 
College, London, UK; Munir Pirmohamed, Institute of Translational Medicine, University of 
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DILIN investigators and coordinators can be found at http://www.dilin.org/publications/ 
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